Core Laboratories (NYSE:CLB) had its price target increased by equities research analysts at JPMorgan Chase & Co. from $118.00 to $121.00 in a report issued on Monday, Stock Target Advisor reports. The firm currently has an “overweight” rating on the oil and gas company’s stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 12.29% from the company’s current price.

A number of other equities analysts also recently weighed in on the stock. Citigroup raised shares of Core Laboratories from a “sell” rating to a “neutral” rating and set a $117.00 target price for the company in a research note on Monday, August 13th. Edward Jones initiated coverage on shares of Core Laboratories in a research note on Tuesday, September 4th. They set a “buy” rating for the company. ValuEngine downgraded shares of Core Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, June 6th. ABN Amro downgraded shares of Core Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, July 2nd. Finally, Royal Bank of Canada reduced their price target on shares of Core Laboratories to $130.00 and set an “outperform” rating for the company in a report on Thursday, July 5th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $115.25.

Shares of NYSE CLB opened at $107.76 on Monday. Core Laboratories has a twelve month low of $87.66 and a twelve month high of $130.34. The firm has a market cap of $4.82 billion, a P/E ratio of 53.88, a PEG ratio of 3.73 and a beta of 1.50. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.53.

Core Laboratories (NYSE:CLB) last announced its earnings results on Wednesday, July 25th. The oil and gas company reported $0.59 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.59. Core Laboratories had a net margin of 13.32% and a return on equity of 64.13%. The business had revenue of $175.48 million during the quarter, compared to the consensus estimate of $174.47 million. During the same quarter last year, the firm earned $0.51 earnings per share. Core Laboratories’s quarterly revenue was up 10.9% on a year-over-year basis. research analysts predict that Core Laboratories will post 2.44 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Signaturefd LLC grew its holdings in shares of Core Laboratories by 403.7% during the second quarter. Signaturefd LLC now owns 811 shares of the oil and gas company’s stock valued at $102,000 after buying an additional 650 shares during the last quarter. WMS Partners LLC acquired a new position in shares of Core Laboratories during the second quarter valued at about $202,000. World Asset Management Inc acquired a new position in shares of Core Laboratories during the second quarter valued at about $205,000. Ingalls & Snyder LLC acquired a new position in shares of Core Laboratories during the second quarter valued at about $225,000. Finally, Creative Planning acquired a new position in shares of Core Laboratories during the second quarter valued at about $226,000.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Further Reading: How is an ETF different from a mutual fund?

Stock Target Advisor

Analyst Recommendations for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.